中美卵巢癌PARP抑制剂应用指南的对比分析和解读

Comparation and interpretation of guidelines for PARP inhibitor in the management of ovarian cancer between China and the United States

多腺苷二磷酸核糖聚合酶(poly ADP ribose polymerase,PARP)抑制剂的问世使卵巢癌的传统治疗模式发生重大变革。随着PARP抑制剂获批用于卵巢癌的适应证逐渐增多,国内外多个肿瘤学会相继颁布了卵巢癌PARP抑制剂临床应用指南/共识,指导PARP抑制剂在卵巢癌中的规范化应用。本文将结合中美PARP抑制剂的可及性、相关基因检测的现状,就中美卵巢癌PARP抑制剂应用指南的推荐进行对比分析和解读,以期为我国PARP抑制剂的规范化、合理化应用提供参考。

The development of poly ADP ribose polymerase(PARP)inhibitor has changed the traditional treatment mode of ovarian cancer.With the increasing number of indications of PARP inhibitor approved for ovarian cancer,several oncology societies have published guidelines or consensus about PARP inhibitors in ovarian cancer to guide the clinical application of PARP inhibitors in ovarian cancer.In the present article,we compare and interpret recommendations of PARP inhibitors in ovarian cancer in China and the United States,considering the difference in the accessibility of PARP inhibitors and the status of genetic testing,in order to provide reference for the standardized and rational use of PARP inhibitors in China.